Global vs. Domestic Healthcare Investing: Evaluating iShares ETFs

Investors seeking exposure to the healthcare sector can choose between broad international diversification through the iShares Global Healthcare ETF (IXJ) or a concentrated domestic approach via the iShares U.S. Pharmaceuticals ETF (IHE). According to [BlackRock](https://www.ishares.com/), IXJ tracks an index of global healthcare companies, while IHE focuses specifically on the performance of U.S.-listed pharmaceutical manufacturers. The primary distinction lies in geographic reach and industry composition; IXJ provides access to 110 international stocks, whereas IHE concentrates its holdings on 56 domestic firms.

Portfolio Composition and Geographic Exposure

The iShares Global Healthcare ETF (IXJ) offers a wide-reaching footprint. Its holdings span developed markets, including the United States, Switzerland, the United Kingdom, and Denmark. By including multinational giants like Eli Lilly, Novo Nordisk, and Novartis, the fund captures growth across pharmaceuticals, biotechnology, and medical device manufacturing. As of the most recent [BlackRock fund data](https://www.ishares.com/us/products/239726/ishares-global-healthcare-etf), the U.S. represents the largest country allocation, but the fund’s international structure mitigates reliance on any single regulatory or economic environment.

Conversely, the iShares U.S. Pharmaceuticals ETF (IHE) is a sector-specific play. It tracks the [Dow Jones U.S. Select Pharmaceuticals Index](https://www.spglobal.com/spdji/en/indices/equity/dow-jones-us-select-pharmaceuticals-index/), which limits its scope to companies classified within the pharmaceutical industry that are traded on U.S. exchanges. This focus results in a narrower, more concentrated portfolio. Investors in IHE are betting specifically on the U.S. drug development pipeline, market pricing power, and domestic regulatory outcomes.

Comparative Analysis: Risk and Concentration

The contrast between these two funds highlights the trade-off between sector concentration and geographic diversification.

| Feature | iShares Global Healthcare (IXJ) | iShares U.S. Pharmaceuticals (IHE) |
| :— | :— | :— |
| Primary Scope | Global healthcare equities | U.S. pharmaceutical companies |
| Diversification | Broad (110+ holdings) | Concentrated (56 holdings) |
| Market Focus | Diversified sub-sectors | Pharmaceutical industry focus |
| Risk Profile | Mitigated by geographic spread | Heightened by domestic sector risk |

Because IHE is concentrated in a single industry, it often experiences higher volatility compared to a broader healthcare index. When U.S. drug pricing legislation or patent cliffs impact the pharmaceutical sector, IHE’s performance typically reacts more sharply than the more diversified IXJ. The latter benefits from the performance of medical technology and equipment companies, which may not move in lockstep with pharmaceutical manufacturers.

Investment Considerations for Healthcare Portfolios

Choosing between these ETFs depends on an investor’s specific objectives. Those looking for a core healthcare holding often favor IXJ for its representative sample of the global industry. By spreading risk across multiple countries and sub-sectors, the fund acts as a proxy for global health spending and innovation.

IHE serves a different purpose: it is a targeted instrument for investors who hold a specific thesis regarding U.S. pharmaceutical companies. Because the fund is limited to 56 stocks, it is more sensitive to the success or failure of individual large-cap drug manufacturers. Before investing, individuals should review the prospectus for each fund to understand the specific expense ratios and the tax implications of holding international versus domestic securities. As with any sector-specific investment, monitoring changes in federal healthcare policy and global regulatory standards remains essential for long-term portfolio management.